Literature DB >> 21358200

Urinary pharmacokinetics and bactericidal activity of finafloxacin (200 and 800 mg) in healthy volunteers receiving a single oral dose.

Florian M E Wagenlehner1, Christine M Wagenlehner, Birgit Blenk, Holger Blenk, Sabine Schubert, Axel Dalhoff, Kurt G Naber.   

Abstract

BACKGROUND: Finafloxacin is a novel 8-cyano-fluoroquinolone under investigation for treatment of urinary tract infection.
METHODS: Urinary concentrations and urinary bactericidal titers (UBT) of finafloxacin 200- and 800-mg single doses in 6 healthy volunteers were measured up to 48 h. UBT were determined for a reference strain and 9 selected clinical uropathogens at the pH of native, acidified (pH 5.5) and alkalinized (pH 8.0) urine.
RESULTS: The mean maximum urine concentrations for 200 and 800 mg finafloxacin were 69.3 mg/l (0-2 h) and 150 mg/l (4-8 h). Median UBT were between 0 and 1:>2,048 and were in general agreement with minimal inhibitory concentrations of strains and urinary pH values. UBT in alkaline urine were significantly lower than those in native or acidic urine, except for Enterococcus faecalis.
CONCLUSIONS: Finafloxacin exhibited significant bactericidal activity against susceptible uropathogens. The urinary bactericidal activity of finafloxacin was enhanced in acidic urine and significantly lower in alkaline urine.
Copyright © 2011 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21358200     DOI: 10.1159/000321028

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  7 in total

1.  Human pharmacokinetics and safety profile of finafloxacin, a new fluoroquinolone antibiotic, in healthy volunteers.

Authors:  Heena Patel; Arne Andresen; Andreas Vente; Hans-Dietrich Heilmann; Will Stubbings; Michael Seiberling; Luis Lopez-Lazaro; Rolf Pokorny; Harald Labischinski
Journal:  Antimicrob Agents Chemother       Date:  2011-06-27       Impact factor: 5.191

Review 2.  Treatment Options for Carbapenem- Resistant Gram-Negative Infections.

Authors:  Moritz Fritzenwanker; Can Imirzalioglu; Susanne Herold; Florian M Wagenlehner; Klaus-Peter Zimmer; Trinad Chakraborty
Journal:  Dtsch Arztebl Int       Date:  2018-05-21       Impact factor: 5.594

Review 3.  Finafloxacin: first global approval.

Authors:  Kate McKeage
Journal:  Drugs       Date:  2015-04       Impact factor: 9.546

4.  Urinary Concentrations and Antibacterial Activity of BAL30072, a Novel Siderophore Monosulfactam, against Uropathogens after Intravenous Administration in Healthy Subjects.

Authors:  Marion Straubinger; Holger Blenk; Kurt G Naber; Florian M E Wagenlehner
Journal:  Antimicrob Agents Chemother       Date:  2016-05-23       Impact factor: 5.191

5.  Explorative Randomized Phase II Clinical Study of the Efficacy and Safety of Finafloxacin versus Ciprofloxacin for Treatment of Complicated Urinary Tract Infections.

Authors:  F Wagenlehner; M Nowicki; C Bentley; M Lückermann; S Wohlert; C Fischer; A Vente; K Naber; A Dalhoff
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

6.  Pharmacodynamics of Finafloxacin, Ciprofloxacin, and Levofloxacin in Serum and Urine against TEM- and SHV-Type Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae Isolates from Patients with Urinary Tract Infections.

Authors:  A Dalhoff; S Schubert; A Vente
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

Review 7.  Chemical structure and pharmacokinetics of novel quinolone agents represented by avarofloxacin, delafloxacin, finafloxacin, zabofloxacin and nemonoxacin.

Authors:  Bela Kocsis; J Domokos; D Szabo
Journal:  Ann Clin Microbiol Antimicrob       Date:  2016-05-23       Impact factor: 3.944

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.